Literature DB >> 24803328

Vitamin D levels and response to biphosphonates in postmenopausal women receiving glucocorticoid therapy.

M Ortego-Jurado1, R Ríos-Fernández, J L Callejas-Rubio, M A Gonzalez-Gay, N Ortego-Centeno.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24803328     DOI： 10.1007/s00198-014-2713-6

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN： 0937-941X            Impact factor:   4.507


× No keyword cloud information.
  9 in total

Review 1.  Clinical review: Do glucocorticosteroids alter vitamin D status? A systematic review with meta-analyses of observational studies.

Authors:  Zoe E Davidson; Karen Z Walker; Helen Truby
Journal:  J Clin Endocrinol Metab       Date:  2011-12-21       Impact factor: 5.958

2.  Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline.

Authors:  Michael F Holick; Neil C Binkley; Heike A Bischoff-Ferrari; Catherine M Gordon; David A Hanley; Robert P Heaney; M Hassan Murad; Connie M Weaver
Journal:  J Clin Endocrinol Metab       Date:  2011-06-06       Impact factor: 5.958

3.  The 25(OH)D level needed to maintain a favorable bisphosphonate response is ≥33 ng/ml.

Authors:  A S Carmel; A Shieh; H Bang; R S Bockman
Journal:  Osteoporos Int       Date:  2012-01-12       Impact factor: 4.507

4.  Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.

Authors:  D M Reid; R A Hughes; R F Laan; N A Sacco-Gibson; D H Wenderoth; S Adami; R A Eusebio; J P Devogelaer
Journal:  J Bone Miner Res       Date:  2000-06       Impact factor: 6.741

5.  25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis.

Authors:  Pilar Peris; Angeles Martínez-Ferrer; Ana Monegal; M Jesús Martínez de Osaba; Africa Muxi; Nuria Guañabens
Journal:  Bone       Date:  2012-04-01       Impact factor: 4.398

6.  Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.

Authors:  S Aubrey Stoch; Kenneth G Saag; Maria Greenwald; Anthony I Sebba; Stanley Cohen; Nadia Verbruggen; Hilde Giezek; Joseph West; Thomas J Schnitzer
Journal:  J Rheumatol       Date:  2009-06-01       Impact factor: 4.666

7.  Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.

Authors:  David M Reid; Jean-Pierre Devogelaer; Kenneth Saag; Christian Roux; Chak-Sing Lau; Jean-Yves Reginster; Philemon Papanastasiou; Alberto Ferreira; Florian Hartl; Taiwo Fashola; Peter Mesenbrink; Philip N Sambrook
Journal:  Lancet       Date:  2009-04-11       Impact factor: 79.321

8.  Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women.

Authors:  Muneaki Ishijima; Yuko Sakamoto; Makoto Yamanaka; Akifumi Tokita; Keiichiro Kitahara; Haruka Kaneko; Hisashi Kurosawa
Journal:  Calcif Tissue Int       Date:  2009-10-01       Impact factor: 4.333

9.  The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.

Authors:  Andrew Deane; Leonor Constancio; Ignac Fogelman; Geeta Hampson
Journal:  BMC Musculoskelet Disord       Date:  2007-01-10       Impact factor: 2.362
  9 in total
  2 in total

1.  Vitamin D and bisphosphonate response.

Authors:  A S Carmel; R S Bockman
Journal:  Osteoporos Int       Date:  2014-05-07       Impact factor: 4.507

2.  Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A "Real-Life" Study.

Authors:  Miguel Ortego-Jurado; José-Luis Callejas-Rubio; Raquel Ríos-Fernández; Juan González-Moreno; Amanda Rocío González Ramírez; Miguel A González-Gay; Norberto Ortego-Centeno
Journal:  J Osteoporos       Date:  2015-06-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.